KENTUCKY – Mattress manufacturer Tempur has outlined plans to introduce an antimicrobial and antiviral technology, which will be integrated within the company’s products by early next year.

The firm’s EPA-registered Surface-Guard treatment has been proven to kill 99 per cent of bacteria on mattresses and, in further trials, was 99 per cent effective against viruses including SARS-CoV-2, a strain of the coronavirus.

Tempur is now pursuing antiviral-efficacy claims approval from the U.S. Food & Drug Administration.

Why Subscribe?

Interested in advertising?

Simply give us a call

Sales: +44 1977 708488

Or if you prefer email, click on the button below and we'll get back to you asap

 

Why Subscribe?

Looking beyond the cutting edge of textile innovation allows you to stay well ahead of the competition. That’s exactly what you get through a subscription to T.EVO – which delivers a refreshing new take on the rapid evolution of today’s dynamic textile sector.

Key T.EVO benefits:

You will learn about:

All this from MCL Global – the fastest growing international textile publisher – which can now offer today’s textile industry a unique preview of how today’s industry will look tomorrow.

In print, online and mobile device formats.